Corporate ActionJun 24, 2026, 06:02 AM
Helus Pharma Prices US$50M Underwritten Offering
AI Summary
Helus Pharma, a clinical-stage pharmaceutical company, announced the pricing of an underwritten offering of 10,309,280 common shares at US$4.85 per share, raising aggregate gross proceeds of US$50 million. The company intends to use the net proceeds to advance its HLP003, HLP004, and HLP005 programs, as well as for working capital and general corporate purposes. The offering, managed by Cantor and Barclays, is expected to close on June 25, 2026.
Key Highlights
- Priced an underwritten offering of 10,309,280 common shares.
- Offering price set at US$4.85 per common share.
- Aggregate gross proceeds from the offering are US$50 million.
- Net proceeds to fund HLP003, HLP004, and HLP005 programs.
- Proceeds also for working capital and general corporate purposes.
- Cantor and Barclays are joint bookrunning managers for the offering.
- Offering expected to close on June 25, 2026.
- HLP003 Phase 3 APPROACH data expected in Q4 2026.
Price Impact
More from HELP